Enhanced 3-epi-25-hydroxyvitamin D3 signal leads to overestimation of its concentration and amplifies interference in 25-hydroxyvitamin D LC-MS/MS assays by Flynn, N et al.
Original Article
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overestimation of its concentration and amplifies
interference in 25-hydroxyvitamin D LC-MS/MS assays
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Abstract
Background: 3-epi-25-hydroxyvitamin D3 (3-epi-25OHD3) interferes in most liquid chromatography-tandem mass
spectrometry (LC-MS/MS) assays for 25-hydroxyvitamin D (25OHD). The clinical significance of this is unclear, with
concentrations from undetectable to 230 nmol/L reported. Many studies have quantified 3-epi-25OHD3 based on
25OHD3 calibrators or other indirect methods, and we speculated that this contributes to the observed variability in
reported 3-epi-25OHD3 concentrations.
Methods: We compared continuous MS/MS infusions of 3-epi-25OHD3 and 25OHD3 solutions, spiked both analytes
into the same serum matrix and analysed patient samples to assess the effect of three different quantitation methods on
3-epi-25OHD3 concentration. Experiments were performed on an LC-MS/MS system using a phenyl column which does
not resolve 3-epi-25OHD3, and a modified method utilizing a Zorbax SB-CN column that chromatographically resolves
3-epi-25OHD3 from 25OHD3.
Results: A greater 3-epi-25OHD3 signal, compared with 25OHD3, was observed during equimolar post-column con-
tinuous infusion of analyte solutions, and following analysis of a serum pool spiked with both analytes. 3-epi-25OHD3
signal enhancement was dependent on mobile phase composition. Compared with 3-epi-25OHD3 calibrators, indirect
quantitation methods resulted in up to 10 times as many samples having 3-epi-25OHD3 concentrations 10nmol/L, and
an approximately fourfold increase in the maximum observed 3-epi-25OHD3 concentration to 95nmol/L.
Conclusions: Enhanced 3-epi-25OHD3 signal leads to overestimation of its concentrations in the indirect quantitation
methods used in many previous studies. The enhanced signal may contribute to greater interference in some 25OHD
LC-MS/MS assays than others. We highlight that equimolar responses cannot be assumed in LC-MS/MS systems, even if
two molecules are structurally similar.
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Introduction
There is interference from 3-epi-25-hydroxyvitamin D3
(3-epi-25OHD3) in most liquid chromatography-
tandem mass spectrometry (LC-MS/MS) 25-
hydroxyvitamin D (25OHD) assays. The clinical
signiﬁcance of this is unclear, with some studies report-
ing concentrations up to 230nmol/L,
1 but others that
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25OHD3.
2,3 This may reﬂect patient selection, since 3-
epi-25OHD3 has been reported to be higher in infants
than adults.
Some studies assume that equimolar 3-epi-25OHD3
and 25OHD3 produce equal signals in LC-MS/MS
assays. 3-epi-25OHD3 quantitation has been based on
25OHD3 calibrators
1 or the diﬀerence in 25OHD3
results between an assay which chromatographically
separatestheepimersandonethatdoesnot.
4Wenoticed
high 3-epi-25OHD3 recovery in our routine 25OHD
LC-MS/MS assay and speculated that 3-epi-25OHD3
produces a greater signal than 25OHD3, enhancing
interference in LC-MS/MS assays and overestimating
3-epi-25OHD3 in assays lacking dedicated calibrators.
To investigate this, we spiked 3-epi-25OHD3 and
25OHD3 into serum, compared analyte infusions and
analysed patient samples to assess diﬀerent 3-
epi-25OHD3 quantitation methods. We used two LC-
MS/MS methods: our routine ‘co-elution method’ in
which 25OHD3 and 3-epi-25OHD3 co-elute, and a
‘resolving method’ that chromatographically separates
the epimers.
Materials and methods
Materials
25OHD3 monohydrate, 3-epi-25OHD3, methanol,
ammonium acetate and zinc sulphate heptahydrate
were from Sigma-Aldrich (St Louis, MO, USA).
26,26,26,27,27,27-d6-25OHD3 was from Synthetica
(Oslo, Norway). Ethanol was from VWR International
(Radnor, PA, USA). Isopropanol and formic acid were
from Fisher Scientiﬁc (Waltham, MA, USA). All solv-
ents were LC-MS grade. Deionized water was taken
from an ELGA Purelab Option-Q15BP water deionizer
(ELGA Process Water, Marlow, UK) with a resistivity
reading of 18.2 MV-cm.
Master solutions of 25OHD3 and 3-epi-25OHD3 at a
concentration of 2.5mmol/L were prepared in ethanol.
The master solution was diluted 1/250 in ethanol to
produce stock solutions of approximately 10mmol/L.
Concentrations of stock 3-epi-25OHD3 and 25OHD3
solutions were determined from their absorbances at
264nm using a molar extinction coeﬃcient
"0¼18,200Lmol
 1cm
 1,
2 a UVIKON spectrophotom-
eter (NorthStar Scientiﬁc, Potton, UK) and quartz cuv-
ettes. 25OHD-deﬁcient human serum pools were
prepared from surplus patient samples with total
25OHD<10nmol/L. Dedicated 3-epi-25OHD3 cali-
brators were prepared in-house from 25OHD-deﬁcient
serum spiked with 3-epi-25OHD3. ChromSystems
3PLUS1 Calibrator Set (Chromsystems, Munich,
Germany) was used unmodiﬁed for 25OHD3
calibration. ChromSystems MassCheck 25-hydroxyvi-
tamin D2/D3 serum controls (Level I and II) were
used as quality control (QC) material for 25OHD2
and 25OHD3. For 3-epi-25OHD3, QC material was
prepared by spiking 3-epi-25OHD3 into a human
serum pool.
Specimen processing
Samples underwent semi-automated solid phase extrac-
tion (SPE)
5 and analysis on a Waters ACQUITY
UPLC-TQD (Waters, Milford, MA, USA). Brieﬂy,
150mL sample was mixed with 20mL
26,26,26,27,27,27-d6-25OHD3 internal standard and
proteins precipitated using ZnSO4 and methanol.
Following centrifugation, 600mL of supernatant was
transferred to a pre-conditioned Oasis HLB (30mm)
mElution plate (Waters, Milford, MA, USA). Sample
cleanup on the mElution plate was via the use of aqueous
methanol solutions. Analytes were eluted by 5% isopro-
panol/95% methanol into 96-well polypropylene plates
(Waters, Milford, MA, USA). The 96-well plate was
heat-sealed, vortexed and centrifuged before analysis.
MS parameters
Analytesunderwentpositiveelectrosprayionizationand
detectionbymultiplereactionmonitoring. The25OHD3
and 3-epi-25OHD3 response was the 401.3>159.1 peak
area (collision energy 28eV) relative to the d6-25OHD3
internal standard 407.3>159.1 peak area (collision
energy 28eV). The 401.3>365.2 transition at a collision
energy of 10eV was used as a qualiﬁer transition for
both 25OHD3 and 3-epi-25OHD3. For infusion experi-
ments, we also monitored the 401.3>383.5 transition at
a collision energy of 10eV. The cone voltage was set at
22V and the capillary voltage at 2.5kV for all 25OHD3
and 3-epi-25OHD3 transitions.
Chromatography
Mobile phase A was water and mobile phase B was
methanol, each supplemented with 2mmol/L ammo-
nium acetate and 0.1% (v/v) formic acid.
The co-elution method used a Waters ACQUITY
UPLC BEH Phenyl column (1.7mm, 2.1 50mm)
(Waters, Milford, MA, USA) with mobile phase
B increasing from 65% to 98% over 3.6min at
0.45ml/min followed by re-equilibration at 65% B.
Analytes co-eluted at 2.7min with a runtime of 5min.
The limit of quantitation was 7nmol/L based on a
signal-to-noise ratio of 10. Inter-batch % coeﬃcient of
variation (%CV) for 25OHD3 was<10% at 42nmol/L
and 97nmol/L. Recoveries of 25OHD3 spiked into
serum were within 20% of target.
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column (1.8mm, 2.1 50mm) (Agilent Technologies,
Santa Clara, CA, USA) with mobile phase B held at
55% for 24min at 0.4mL/min to resolve 25OHD3
(retention time 17.0min) from 3-epi-25OHD3 (retention
time 19.6min). The column was washed at 98% B and
reequilibrated at 55% B. The limit of quantitation was
10nmol/L based on a signal-to-noise ratio of 10. Inter-
batch %CVs were<10% at 42nmol/L and 91nmol/L
for 25OHD3, and 7.8% at 15nmol/L and 11.7% at
50nmol/L for 3-epi-25OHD3. Recoveries of 25OHD3
and 3-epi-25OHD3 spiked into serum were within 20%
of target.
Spiking experiments
For spiking experiments, 25OHD-deﬁcient serum was
spiked with either 25OHD3 or 3-epi-25OHD3. In the
co-elution method, the response for both sets of samples
was the combined (25OHD3þ3-epi-25OHD3) peak
area divided by the d6-25OHD3 internal standard peak
area,as25OHD3and3-epi-25OHD3co-eluted.Thecon-
centration was calculated astheconcentration measured
in the base pool (9nmol/L) plus the concentration of
25OHD3 or 3-epi-25OHD3 spiked in the sample.
In the resolving method, the response for 25OHD3
spiked serum was the 25OHD3 peak area divided by the
d6-25OHD3 internal standard peak area, and the con-
centration was the 25OHD3 concentration measured in
the base pool (10nmol/L), plus the concentration of
25OHD3 spiked in the sample. The response for
3-epi-25OHD3 was the 3-epi-25OHD3 peak area
divided by the d6-25OHD3 internal standard peak
area, and the concentration was the 3-epi-25OHD3
concentration spiked (3-epi-25OHD3 was not detected
in the base pool).
Figure 1. Measured response for 25OHD-deficient serum spiked with 25OHD3 and 3-epi-25OHD3 in (a) the co-elution method
and (b) the resolving method.
354 Annals of Clinical Biochemistry 51(3)
 at University College London on June 25, 2015 acb.sagepub.com Downloaded from Infusion experiments
For infusion experiments, 1mmol/L 3-epi-25OHD3 and
25OHD3 solutions were prepared by dilution of stock
solutions with 80:20 methanol:isopropanol and infused
post-column with mobile phase.
Analysis of patients’ samples
Samples were analysed from 341 patients, of which 211
were randomly selected and 130 were chosen from chil-
dren (<18 years) or because they had 25OHD concen-
trations>50nmol/L. The study included 227 female
and 113 male patients (gender unknown for one sub-
ject). Seven subjects were aged<1 year (youngest 8
days), 87 aged 1–18 years, and 247 aged>18 years
(oldest 88 years). Quantiﬁcation of 3-epi-25OHD3 was
performed:
1. using dedicated calibrators in the resolving method;
2. using 25OHD3 calibrators in the resolving method;
3. as the diﬀerence between 25OHD3 results in the
co-elution and resolving methods.
Results
Equimolar 3-epi-25OHD3 gave a greater response than
25OHD3 when the same serum pool was spiked with
either compound, being approximately 60% greater in
the co-elution method, and 20% greater in the resolving
method (Figure 1). This was also true when analytes
were quantiﬁed using the 401.3>365.2 transition
(data not shown).
When infusing equimolar solutions into the MS, the
3-epi-25OHD3 signal was greater than 25OHD3 for the
401.3>159.1 transition (Figure 2). The epimer signal
enhancement during analyte elution ( 2.7min) in the
co-elution method (Figure 2(a)) was double the signal
Figure 2. Chromatographs for the 401.3>159.1 transition during infusions of equal concentrations of 3-epi-25OHD3 and 25OHD3.
(a) Infusion with the co-elution method chromatography conditions; (b) Infusion with the resolving method chromatography condi-
tions; (c) Infusions where the mobile phase composition was changed in regular intervals. Signal intensity is given as a percentage of the
ion count shown in the top right of each panel.
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(Figure 2(b)). This was veriﬁed on a second independ-
ently prepared set of infusion solutions. Increasing
methanol concentrations increased the diﬀerence
between epimer signals (Figure 2(c)). The same pattern
was observed when infusions were monitored with
either 401.3>365.2 (Figure 3) or 401.3>383.5
(Figure 4) transitions.
When quantiﬁed using dedicated calibrators, 3-
epi-25OHD3 was present at between 10 and 22nmol/L
in ﬁve of 341 patient samples (Table 1). Using 25OHD3
calibrators, the number of samples which had 3-
epi-25OHD3 concentrations 10nmol/L was increased
two to threefold. Quantitation of 3-epi-25OHD3 as the
diﬀerence in 25OHD3 between co-elution and resolving
methods resulted in 10 times as many samples with 3-
epi-25OHD3 10nmol/L, and an approximately four-
fold increase in the maximum concentration to
95nmol/L.
Discussion
We demonstrated enhanced 3-epi-25OHD3 signal rela-
tive to equimolar 25OHD3 during infusions and in
spiked human serum. Enhanced signal caused overesti-
mation of 3-epi-25OHD3 concentrations when quanti-
ﬁed using 25OHD3 calibrators or as the diﬀerence in
25OHD3 results between an assay that chromatogra-
phically separates the epimers and a method in which
they co-elute.
It is unclear if enhanced 3-epi-25OHD3 signal occurs
in all LC-MS/MS systems. In a Vitamin D external
quality assessment scheme (DEQAS), 3-epi-25OHD3
interference studies (sample 405) showed an average
cross-reactivity>100% in LC-MS/MS methods.
6 The
wide spread of LC-MS/MS results for this sample
(%CV 23.5% vs. %CV 10.8% in the base sample) sug-
gest variable 3-epi-25OHD3 interference, possibly due
to variable enhancement of 3-epi-25OHD3 signal. Our
analyte infusion studies showed signal enhancement for
Figure 3. Chromatographs for the 401.3>365.2 transition during infusions of equal concentrations of 3-epi-25OHD3 and 25OHD3.
(a) Infusion with the co-elution method chromatography conditions; (b) Infusion with the resolving method chromatography condi-
tions; (c) Infusion where the mobile phase composition was changed in regular intervals. Signal intensity is given as a percentage of the
ion count shown in the top right of each panel.
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sitions used by most LC-MS/MS 25OHD assays,
7 sug-
gesting that many LC-MS/MS systems might be
aﬀected by 3-epi-25OHD3 signal enhancement.
In both infusion and spiking experiments, the
3-epi-25OHD3 signal enhancement was two to three-
fold greater in the co-elution than in the resolving
method. Infusion experiments showed increasing
signal enhancement at higher methanol concentrations;
since 3-epi-25OHD3 elutes at approximately 55%
methanol in the resolving method and approximately
80% in the co-elution method, this may explain the
greater signal enhancement in the latter. This depend-
ence of signal enhancement on mobile phase compos-
ition may also contribute to the variable 3-epi-25OHD3
interference between DEQAS participants in the inter-
ference studies noted above.
As the molar extinction coeﬃcient for 3-epi-25OHD3
is unknown, we used the same value as for 25OHD3
to assign concentration, an approach used by others.
2
The inversion of stereochemistry at C3 is chemically dis-
tant from the triene chromophore, but diﬀerences in UV
absorption cannot be excluded. However, we would not
expect the diﬀerence in UV absorption to exceed
the<10% diﬀerence between 25OHD3 ("0¼18,200L
mol
 1cm
 1) and 25OHD2 ("0¼19,400L mol
 1cm
 1)
absorbance. Any diﬀerence in 3-epi-25OHD3 and
25OHD3 concentrations due to inaccurate assignments
of molar extinction coeﬃcients cannot explain the dif-
ferent magnitudes of signal enhancement between the
two methods, the variation of signal enhancement
with methanol concentrations or the over-recovery of
3-epi-25OHD3 by LC-MS/MS users in a DEQAS
3-epi-25OHD3 interference experiment.
6
Signal enhancement could occur due to extraction,
ionization or fragmentation diﬀerences. As 3-
epi-25OHD3 enhancement was observed during infu-
sion experiments, extraction diﬀerences alone cannot
be responsible. Since 3-epi-25OHD3 and 25OHD3 frag-
ment similarly
8 and enhancement was observed for
Figure 4. Chromatographs for the 401.3>383.5 transition during infusions of equal concentrations of 3-epi-25OHD3 and 25OHD3.
(a) Infusion with the co-elution method chromatography conditions; (b) Infusion with the resolving method chromatography condi-
tions; (c) Infusion where the mobile phase composition was changed in regular intervals. Signal intensity is given as a percentage of the
ion count shown in the top right of each panel.
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tions during infusion experiments, signal enhancement
is likely due to greater 3-epi-25OHD3 ionization.
Ion suppressing substances could cause ionization
diﬀerences in the resolving method if co-eluting with
either analyte. However, no ion suppression was
observed when analytes were co-infused with extracted
serum during validation of the resolving method (data
not shown), and infusion experiments show a consist-
ently greater signal for 3-epi-25OHD3. Ion suppression
is an unsatisfactory explanation in the co-elution
method, where analytes would be subjected to similar
ion suppression. We suggest that intrinsic diﬀerences
between 3-epi-25OHD3 and 25OHD3 ionization exist,
modulatedbyfactorssuchasmobile phasecomposition.
In some cases, quantitation of 3-epi-25OHD3 as the
diﬀerence between 25OHD3 concentrations in the co-
elution and resolving methods caused concentrations to
increase four to ﬁvefold compared with using dedicated
calibrators. This cannot be explained solely by 3-
epi-25OHD3 signal enhancement and could be due to
other unidentiﬁed 25OHD3 isobars.
Studies using dedicated 3-epi-25OHD3 calibrators
reported low concentrations of this analyte, forming a
minor fraction of total 25OHD3,
2,3 whereas studies
using indirect quantitation have reported higher results,
with 3-epi-25OHD3 in excess of 25OHD3 in some indi-
viduals.
1,4 Our results suggest that previously unrecog-
nized diﬀerences in epimer ionization contribute to
these discrepancies.
Accurate 3-epi-25OHD3 measurement could also be
aﬀected by the lack of an isotope labeled 3-epi-25OHD3
internal standard, which was unavailable during this
study. In the resolving method, we used d6-25OHD3
as internal standard for 3-epi-25OHD3 and ensured
that chromatography was suﬃcient to resolve ion sup-
pressing substances.
The resolving method was developed to investigate 3-
epi-25OHD3 interference in 25OHD analysis. The limit
of detection of the method is higher than has been
reported for other 3-epi-25OHD3 assays.
2,3 However,
our intention was not to develop a reference method
for 3-epi-25OHD3 but rather to demonstrate the eﬀect
that diﬀerent quantitation models can have on 3-
epi-25OHD3 quantitation. Similarly, the resolving
method’s extended runtime precludes routine use.
However, 3-epi-25OHD3 can be partially separated
within 6.5min.
9 We advise that LC-MS/MS users quan-
titatively assess 3-epi-25OHD3 interference in their
25OHD assays and consider modiﬁcations to minimize
interference. We also advise using 3-epi-25OHD3 cali-
brators if direct quantitation of this isomer is required.
Non-stoichiometric cross-reactivity is a familiar con-
cept in immunoassays; we highlight that equimolar
responses cannot be assumed in LC-MS/MS systems,
even if two molecules are structurally similar.
Furthermore, as cross-reactivity can diﬀer between
immunoassays due to diﬀering antibody speciﬁcity
and/or assay conﬁguration, variable ionization is a pos-
sible mechanism for diﬀering degrees of interference
between LC-MS/MS assays.
Acknowledgements
None
Declaration of conflicting interests
None declared
Funding
This research received no speciﬁc grant from any funding
agency in the public, commercial, or not-for-proﬁt sectors.
Ethical approval
Not required
Guarantor
AD
Contributorship
All authors contributed to study design. NF and FL per-
formed experiments. NF analysed data and wrote the ﬁrst
draft of the manuscript. All authors reviewed and edited the
manuscript and approved the ﬁnal version.
Table 1. 3-epi-25OHD3 measurement in 341 samples using three different modes of quantitation.
3-epi-25OHD3
calibrators
25OHD3
calibrators
Difference between
25OHD3 results
Number of samples with [3-epi-25OHD3] 10nmol/L (% of all samples) 5 (1.5%) 13 (4%) 50 (15%)
Maximum [3-epi-25OHD3] nmol/L 22 23 95
Maximum [3-epi-25OHD3] as % of 25OHD3 concentration 20 27 78
Using 3-epi-25OHD3 calibrators in the resolving method, using 25OHD3 calibrators in the resolving method, and as the difference between 25OHD3
results in the co-elution and resolving methods.
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